[新型激素药物治疗去势抵抗性前列腺癌的疗效与问题]
[Efficacy and problems of new hormonal agents for the treatment of castration resistant prostate cancer].
作者信息
Hakariya Tomoaki, Sakai Hideki
出版信息
Nihon Rinsho. 2016 Jan;74(1):137-42.
Enzalutamide and abiraterone acetate are novel drugs for the treatment of castration resistant prostate cancer (CRPC). These agents clearly demonstrated improvements in PFS and OS in patients with CRPC in large randomized Phase III trials. However, the problems exist such as side effects, PSA flare, treatment biomarkers and sequence of the treatment. Further research is necessary to determine the optimal sequence of the treatment or the optimal combination approach with both enzalutamide and abiraterone acetate. It is also necessary to find predictive factors (clinical or molecular) to assist the clinician in making better treatment decisions in an individualized manner.
恩杂鲁胺和醋酸阿比特龙是用于治疗去势抵抗性前列腺癌（CRPC）的新型药物。在大型随机III期试验中，这些药物在CRPC患者中明显显示出无进展生存期（PFS）和总生存期（OS）的改善。然而，存在诸如副作用、前列腺特异性抗原（PSA）激增、治疗生物标志物和治疗顺序等问题。有必要进行进一步研究以确定最佳治疗顺序或恩杂鲁胺与醋酸阿比特龙的最佳联合治疗方法。还有必要找到预测因素（临床或分子），以帮助临床医生以个体化方式做出更好的治疗决策。
Zotero 插件